Alvotech (ALVO)

$8.40 +0.25 (3.07%)
Market Cap 2.46B
Revenue (ttm) 489.68M
Net Income (ttm) -231.86M
EPS (ttm) N/A
PE Ratio 18.70
Forward PE 44.53
Profit Margin -47.35%
Debt to Equity Ratio -6.45
Volume 400,000
Avg Vol 389,408
Day's Range N/A - N/A
Shares Out 301.48M
Stochastic %K 37%
Beta 0.10
Analysts Strong Sell
Price Target $17.50

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
9, Rue de Bitbourg, Luxembourg, Luxembourg
PremarketAnalysis
PremarketAnalysis Oct. 15 at 5:10 PM
$ALVO SignalEngine: MM Infl (Neutral), Algo Vol 55%, Org Vol 45%, BRX 20% Algo Int: Low pressure phase..drift and hold expected after reversal trigger. Momentum Feed: https://premarketanalysis.com/#momentum=ALVO
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 12:54 PM
Morgan Stanley updates rating for Alvotech ( $ALVO ) to Overweight, target set at 14.
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 5:18 PM
$ALVO Really good write-up that perfectly summarizes ALVO's present situation. So if you want to bring your ALVO knowledge up to date or just discover ALVO, this is required reading. https://beyondspx.com/quote/ALVO/analysis/alvotech-s-commercial-breakthrough-a-biosimilar-growth-story-unfolding-nasdaq-alvo
0 · Reply
theroyalflush
theroyalflush Oct. 1 at 8:19 PM
Pharma Alert! Keep an eye on the biosimilar market. Companies rapidly expanding their portfolios beyond immunology, like $ALVO, are showing massive revenue growth potential. Strategic partnerships for development and commercialization are mitigating risk and accelerating product launches into high-growth areas like ophthalmology and oncology. Check the charts! 📈 Here are some healthcare companies to keep and eye on: $IBB (iShares Nasdaq Biotechnology ETF - broad biotech exposure) $XLV (Health Care Select Sector SPDR Fund - broad healthcare sector) $MRNA (A popular, highly-discussed pharmaceutical/biotech name)
0 · Reply
dougc33
dougc33 Sep. 23 at 5:11 PM
$ALVO Alvotech was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Tuesday,Briefing.com reports. The firm currently has a $14.00 price objective on the stock. Deutsche Bank Aktiengesellschaft's target price points to a potential upside of 74.78% from the stock's current price. ALVO has been the topic of several other reports. UBS Group dropped their price objective on Alvotech from $16.00 to $14.00 and set a "buy" rating on the stock in a research report on Friday, July 18th. Zacks Research cut Alvotech from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Alvotech currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.00.
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 4:42 PM
$ALVO vs. $TEVA — which generic giant wins this battle? Alvotech is riding partnership-driven momentum with biosimilar revenues climbing, while Teva leans on scale but faces debt and mounting competition. Full breakdown here 👉 https://www.zacks.com/stock/news/2755898/alvotech-vs-teva-pharma-which-generic-drugmaker-is-the-better-play?cid=sm-stocktwits-2-2755898-teaser-13773&ADID=SYND_STOCKTWITS_TWEET_2_2755898_TEASER_13773
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 3:42 PM
$ALVO vs. $TEVA: Which biosimilar play is safer right now? 🤔 Alvotech's partnership-driven model has fueled a 200% product revenue surge in H1 2025, reaffirming its $600M-$700M full-year target, while Teva faces competitive pressures and a high debt load. Both stocks hold a Zacks Rank #3 (Hold), but ALVO’s growth momentum makes it a compelling option despite its higher valuation. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2755898/alvotech-vs-teva-pharma-which-generic-drugmaker-is-the-better-play?cid=sm-stocktwits-2-2755898-body-13738&ADID=SYND_STOCKTWITS_TWEET_2_2755898_BODY_13738
0 · Reply
JarvisFlow
JarvisFlow Sep. 23 at 12:42 PM
Deutsche Bank updates rating for Alvotech ( $ALVO ) to Buy, target set at 14.
0 · Reply
deedah
deedah Sep. 23 at 11:31 AM
$ALVO DEUTSCHE Bank raises Alvotech from HOLD to BUY , raises price target to $22
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 22 at 10:54 AM
WATCHLIST SEP 22 2025 $ALVO Alvotech Wins EU Panel Backing For Biosimilar To Prolia And Xgeva, Expanding Affordable Bone Disease Treatments $JSPR BTIG Maintains Buy on Jasper Therapeutics, Lowers Price Target to $7 $PINC Premier, Inc. Announces Definitive Agreement to Be Acquired by Patient Square Capital in Transaction Valued at $2.6 Billion $LAES SEALSQ Signs MoU With Seoul Metropolitan Government And Invest Seoul To Establish Post-Quantum Semiconductor Personalization, Research And Design Center In Seoul $NI NiSource Subsidiary NIPSCO Enters Contract To Provide Electric Service To Investment Grade Customer's Data Centers
0 · Reply
Latest News on ALVO
Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 22, 2025, 5:00 AM EDT - 3 days ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Alvotech: Promising Vertically Integrated Biosimilar Platform

Oct 15, 2025, 4:18 AM EDT - 10 days ago

Alvotech: Promising Vertically Integrated Biosimilar Platform

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV AMGN ARKG AZN BIIB BMY GILD

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Oct 6, 2025, 4:40 AM EDT - 19 days ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 6:15 AM EDT - 4 weeks ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 22, 2025, 4:30 AM EDT - 4 weeks ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 19, 2025, 7:45 AM EDT - 5 weeks ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 1:28 PM EDT - 6 weeks ago

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Sep 4, 2025, 9:15 AM EDT - 7 weeks ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 21, 2025, 4:30 AM EDT - 2 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 20, 2025, 6:05 AM EDT - 2 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 11:38 AM EDT - 2 months ago

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 2 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 2 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Aug 6, 2025, 8:00 AM EDT - 2 months ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 10, 2025, 4:40 AM EDT - 3 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 3 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 9, 2025, 4:30 AM EDT - 3 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 3, 2025, 7:02 PM EDT - 4 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Granting of Stock Options and Vesting of Restricted Share Units

Jul 1, 2025, 7:54 PM EDT - 4 months ago

Granting of Stock Options and Vesting of Restricted Share Units

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Jul 1, 2025, 4:00 AM EDT - 4 months ago

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 26, 2025, 4:15 AM EDT - 4 months ago

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Main Results of 2025 Annual and Extraordinary General Meeting

Jun 25, 2025, 4:45 PM EDT - 4 months ago

Main Results of 2025 Annual and Extraordinary General Meeting

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 4 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 4 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 4 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 4 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:20 PM EDT - 4 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:18 PM EDT - 4 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 5 months ago

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 5 months ago

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Jun 5, 2025, 1:56 PM EDT - 5 months ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

MRK RDY

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Jun 4, 2025, 10:29 PM EDT - 5 months ago

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Jun 4, 2025, 11:32 AM EDT - 5 months ago

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Jun 4, 2025, 7:45 AM EDT - 5 months ago

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

Jun 2, 2025, 9:15 AM EDT - 5 months ago

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

May 28, 2025, 6:15 AM EDT - 5 months ago

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Alvotech Annual General Meeting to be held June 25, 2025

May 26, 2025, 2:06 PM EDT - 5 months ago

Alvotech Annual General Meeting to be held June 25, 2025

Transactions of Managers and Closely Associated Persons

May 23, 2025, 12:11 PM EDT - 5 months ago

Transactions of Managers and Closely Associated Persons

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 19, 2025, 3:15 AM EDT - 5 months ago

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

May 19, 2025, 2:30 AM EDT - 5 months ago

Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm

May 16, 2025, 1:52 PM EDT - 5 months ago

Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm

Alvotech (ALVO) Q1 2025 Earnings Call Transcript

May 11, 2025, 1:08 AM EDT - 5 months ago

Alvotech (ALVO) Q1 2025 Earnings Call Transcript

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 8, 2025, 2:30 AM EDT - 6 months ago

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 4:45 PM EDT - 6 months ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 4:45 PM EDT - 6 months ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

May 7, 2025, 5:00 AM EDT - 6 months ago

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

May 2, 2025, 8:30 AM EDT - 6 months ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

May 2, 2025, 8:30 AM EDT - 6 months ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

Apr 30, 2025, 4:39 PM EDT - 6 months ago

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

PremarketAnalysis
PremarketAnalysis Oct. 15 at 5:10 PM
$ALVO SignalEngine: MM Infl (Neutral), Algo Vol 55%, Org Vol 45%, BRX 20% Algo Int: Low pressure phase..drift and hold expected after reversal trigger. Momentum Feed: https://premarketanalysis.com/#momentum=ALVO
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 12:54 PM
Morgan Stanley updates rating for Alvotech ( $ALVO ) to Overweight, target set at 14.
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 5:18 PM
$ALVO Really good write-up that perfectly summarizes ALVO's present situation. So if you want to bring your ALVO knowledge up to date or just discover ALVO, this is required reading. https://beyondspx.com/quote/ALVO/analysis/alvotech-s-commercial-breakthrough-a-biosimilar-growth-story-unfolding-nasdaq-alvo
0 · Reply
theroyalflush
theroyalflush Oct. 1 at 8:19 PM
Pharma Alert! Keep an eye on the biosimilar market. Companies rapidly expanding their portfolios beyond immunology, like $ALVO, are showing massive revenue growth potential. Strategic partnerships for development and commercialization are mitigating risk and accelerating product launches into high-growth areas like ophthalmology and oncology. Check the charts! 📈 Here are some healthcare companies to keep and eye on: $IBB (iShares Nasdaq Biotechnology ETF - broad biotech exposure) $XLV (Health Care Select Sector SPDR Fund - broad healthcare sector) $MRNA (A popular, highly-discussed pharmaceutical/biotech name)
0 · Reply
dougc33
dougc33 Sep. 23 at 5:11 PM
$ALVO Alvotech was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Tuesday,Briefing.com reports. The firm currently has a $14.00 price objective on the stock. Deutsche Bank Aktiengesellschaft's target price points to a potential upside of 74.78% from the stock's current price. ALVO has been the topic of several other reports. UBS Group dropped their price objective on Alvotech from $16.00 to $14.00 and set a "buy" rating on the stock in a research report on Friday, July 18th. Zacks Research cut Alvotech from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Alvotech currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.00.
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 4:42 PM
$ALVO vs. $TEVA — which generic giant wins this battle? Alvotech is riding partnership-driven momentum with biosimilar revenues climbing, while Teva leans on scale but faces debt and mounting competition. Full breakdown here 👉 https://www.zacks.com/stock/news/2755898/alvotech-vs-teva-pharma-which-generic-drugmaker-is-the-better-play?cid=sm-stocktwits-2-2755898-teaser-13773&ADID=SYND_STOCKTWITS_TWEET_2_2755898_TEASER_13773
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 3:42 PM
$ALVO vs. $TEVA: Which biosimilar play is safer right now? 🤔 Alvotech's partnership-driven model has fueled a 200% product revenue surge in H1 2025, reaffirming its $600M-$700M full-year target, while Teva faces competitive pressures and a high debt load. Both stocks hold a Zacks Rank #3 (Hold), but ALVO’s growth momentum makes it a compelling option despite its higher valuation. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2755898/alvotech-vs-teva-pharma-which-generic-drugmaker-is-the-better-play?cid=sm-stocktwits-2-2755898-body-13738&ADID=SYND_STOCKTWITS_TWEET_2_2755898_BODY_13738
0 · Reply
JarvisFlow
JarvisFlow Sep. 23 at 12:42 PM
Deutsche Bank updates rating for Alvotech ( $ALVO ) to Buy, target set at 14.
0 · Reply
deedah
deedah Sep. 23 at 11:31 AM
$ALVO DEUTSCHE Bank raises Alvotech from HOLD to BUY , raises price target to $22
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 22 at 10:54 AM
WATCHLIST SEP 22 2025 $ALVO Alvotech Wins EU Panel Backing For Biosimilar To Prolia And Xgeva, Expanding Affordable Bone Disease Treatments $JSPR BTIG Maintains Buy on Jasper Therapeutics, Lowers Price Target to $7 $PINC Premier, Inc. Announces Definitive Agreement to Be Acquired by Patient Square Capital in Transaction Valued at $2.6 Billion $LAES SEALSQ Signs MoU With Seoul Metropolitan Government And Invest Seoul To Establish Post-Quantum Semiconductor Personalization, Research And Design Center In Seoul $NI NiSource Subsidiary NIPSCO Enters Contract To Provide Electric Service To Investment Grade Customer's Data Centers
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 19 at 11:49 AM
$ALVO Alvotech's Commercialization Partner In Japan, Fuji Pharma, Receives Marketing Approval For Three New Biosimilars From Japanese Ministry Of Health, Labor And Welfare
0 · Reply
ZacksResearch
ZacksResearch Sep. 18 at 1:36 PM
$ALVO's product revenues surged over 200% driven by sales of Simlandi and Selarsdi marketed by $TEVA! 🚀 🤝 Strategic alliances with $TEVA & Stada boost biosimilar sales 💰 Diversified income streams with upfront & milestone payments 🔍 Expansion into ophthalmology & plans in neurology & oncology Discover how ALVO is positioning for future growth 👉 https://www.zacks.com/stock/news/2753318/heres-how-alvos-commercial-partnerships-are-driving-top-line-growth?cid=sm-stocktwits-2-2753318-body-12997&ADID=SYND_STOCKTWITS_TWEET_2_2753318_BODY_12997
0 · Reply
dbr_island
dbr_island Sep. 18 at 12:38 PM
$ALVO there it goes…. I want $3 next CAPS loading 🚢📦📦📦📦🚨 Here’s why👇 YOU IGNORE SMART MONEY YOU IGNORE BIG MONEY LIKE ATCH
0 · Reply
ZacksResearch
ZacksResearch Sep. 18 at 12:36 PM
$ALVO’s growth engine? Partnerships. 🚀 Collabs are fueling biosimilar revenue, adding new approvals, and expanding a diversified pipeline across major therapies. See how this strategy is powering top-line growth 👉 https://www.zacks.com/stock/news/2753318/heres-how-alvos-commercial-partnerships-are-driving-top-line-growth?cid=sm-stocktwits-2-2753318-teaser-12996&ADID=SYND_STOCKTWITS_TWEET_2_2753318_TEASER_12996
0 · Reply
ZacksResearch
ZacksResearch Sep. 9 at 1:51 PM
$ALVO near 52-week low — time to buy the dip or hold? 🤔 📉 38% YTD decline against industry’s 5% growth 🤝 Strategic partnerships with TEVA & RDY drive over 200% increase in product revenues in 1H 2025 📈 Rising EPS estimates and a Zacks Rank #3 (Hold) suggest growth potential Discover the full analysis here 👉 https://www.zacks.com/stock/news/2748596/alvo-stock-trades-near-52-week-low-should-you-buy-hold-or-sell?cid=sm-stocktwits-2-2748596-body-11480&ADID=SYND_STOCKTWITS_TWEET_2_2748596_BODY_11480
0 · Reply
ZacksResearch
ZacksResearch Sep. 9 at 12:51 PM
$ALVO near its 52-week low — bargain or falling knife? ⚡️ The stock is trading close to its yearly bottom, putting investors in a tough spot: buy, hold, or sell at these levels. Full breakdown here 👉 https://www.zacks.com/stock/news/2748596/alvo-stock-trades-near-52-week-low-should-you-buy-hold-or-sell?cid=sm-stocktwits-2-2748596-teaser-11469&ADID=SYND_STOCKTWITS_TWEET_2_2748596_TEASER_11469
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 9:46 AM
WATCHLIST AUG 21 2025 $INSG Inseego Corp And OneSource Enters Partnership To Launch Janus, A New Managed Service That Combines Inseego's 5G Fixed Wireless Access Devices With OneSource's Connectivity Services $NAMS NewAmsterdam Pharma And Piramal Pharma Solutions Invest Multi-Million Dollars In Dedicated Oral Solid Dosage Suite At Sellersville Pennsylvania Facility $ALVO Advanz Pharma And Alvotech Receive European Commission Approval For Mynzepli Biosimilar To Eylea For Treatment Of Retinal Diseases Including Neovascular AMD $WRD WeRide Teams With Bosch To Launch Human-Like One-Stage Driving Tech, Plans Mass Production In 2025 $CECO Needham Maintains Buy on CECO Environmental, Raises Price Target to $52
0 · Reply
saad545
saad545 Aug. 21 at 9:33 AM
$ALVO https://finance.yahoo.com/news/advanz-pharma-alvotech-receive-european-083000775.html
0 · Reply
saad545
saad545 Aug. 18 at 2:20 PM
$ALVO
0 · Reply
TravelingTraderNL
TravelingTraderNL Aug. 14 at 7:01 PM
$ALVO +12% from day low
0 · Reply
TravelingTraderNL
TravelingTraderNL Aug. 14 at 6:43 PM
$ALVO +10% from day low
0 · Reply
TravelingTraderNL
TravelingTraderNL Aug. 14 at 5:27 PM
$ALVO green end of day
0 · Reply